Success Metrics

Clinical Success Rate

100.0%

Based on 4 completed trials

Completion Rate

100%(4/4)

Active Trials

3(43%)

Results Posted

0%(0 trials)

Phase Distribution

Ph early_phase_1

14%

Ph phase_1

14%

Ph phase_4

14%

Ph phase_2

57%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution7 total trials

Early Phase 1First-in-human

1(14.3%)

Phase 1Safety & dosage

1(14.3%)

Phase 2Efficacy & side effects

4(57.1%)

Phase 4Post-market surveillance

1(14.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Completed(4)

Detailed Status

Completed4

Recruiting3

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Early Phase 11 (14.3%)

Phase 11 (14.3%)

Phase 24 (57.1%)

Phase 41 (14.3%)

Trials by Status

completed457%

recruiting343%

Recent Activity

3 active trials

Showing 5 of 7

recruitingphase_1

Clinical Trials (7)

Showing 7 of 7 trials

NCT07679542Phase 1

Dihydroartemisinin for MAFLD

Recruiting

NCT07007078Early Phase 1

Efficacy of Dihydroartemisinin for Treating Acne Vulgaris

Recruiting

NCT06417099Phase 2

Efficacy of Dihydroartemisinin for Treating PCOS

Completed

NCT06842524Phase 2

Dihydroartemisinin for the Treatment of Polycystic Ovary Syndrome

Recruiting

NCT05465135Phase 4

The Effect of Dihydroartemisinin in PCOS

Completed

NCT06036030Phase 2

Combination Momordica Charantia Extract and Primaquine Againts Plasmodium Falciparum Uncomplicated and Plasmodium Vivax Uncomplicated Treatment in Manokwari, West Papua

Completed

NCT05829187Phase 2

Momordica Charantia and Dihydroartemisinin-piperaquined-primaquine for Uncomplicated Plasmodium Falciparum Malaria Patients in Southwest Sumba Regency

Completed

All 7 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 7